Observational studyDiabetes, obesity & metabolism2026
Prognostic Implications of Coronary Microvascular Dysfunction in ST-Elevation Myocardial Infarction by Obesity Status.
Observational study in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Implications of Coronary Microvascular Dysfunction in ST-Elevation Myocardial Infarction by Obesity Status.Diabetes, obesity & metabolism · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsThis study aimed to assess the association of coronary microvascular dysfunction (CMD) assessed by the angiography-derived index of microcirculatory resistance (angio-IMR) with long-term cardiovascular outcomes in ST-elevation myocardial infarction (STEMI) patients stratified by obesity categories. MATERIALS AND
methodsIn this multicentre prospective cohort, STEMI patients undergoing primary percutaneous coronary intervention (PPCI) were enrolled. Patients were stratified by obesity categories (healthy weight: BMI < 24 kg/m
resultsOf 497 STEMI patients, CMD prevalence was comparable across BMI groups (p = 0.875). The cumulative incidence of MACCE was significantly higher in the CMD group than in the non-CMD group among patients with obesity (33.3% vs. 15.0%, log-rank p = 0.016), but not among those with overweight (19.6% vs. 15.9%, log-rank p = 0.565) and healthy weight (20.7% vs. 17.4%, log-rank p = 0.673). CMD independently predicted MACCE in obesity (adjusted HR; p = 0.020), with consistent results for continuous angio-IMR (adjusted HR 1.03, p < 0.001). No associations existed in patients with overweight or healthy weight. Additionally, CMD was associated with a higher prevalence of intramyocardial haemorrhage exclusively in obesity (adjusted OR 4.40, p = 0.003) and overweight (adjusted OR 2.65, p = 0.007).
conclusionCMD assessed by angio-IMR is an independent predictor of MACCE in STEMI patients with obesity, but not those without obesity. Patients with obesity and STEMI who have CMD may represent a high-risk subgroup for future trials of microvascular-protective therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.